Management of pain with diclofenac after femtosecond-assisted laser in situ
keratomileusis.
Author(s): Parker J, Tandon A, Shtein RM, Soong HK, Cooney TN, Musch DC, Mian SI.
Affiliation(s): Department of Ophthalmology and Visual Sciences, University of Michigan Medical
School, Ann Arbor, Michigan, USA.
Publication date & source: 2011, J Cataract Refract Surg. , 37(3):569-73
PURPOSE: To evaluate the safety and efficacy of topical diclofenac sodium 0.1%
after femtosecond laser-assisted laser in situ keratomileusis (LASIK).
SETTING: W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan,
USA.
DESIGN: Clinical trial.
METHODS: Pain was assessed in patients treated with topical diclofenac sodium
0.1% or artificial tears immediately after LASIK using a numeric pain scale and a
combined picture-numeric pain scale 0, 2, 4, 12, and 24 hours postoperatively.
Visual outcomes and complications were noted up to 24 hours.
RESULTS: The study enrolled 100 eyes of 50 patients. Patients treated with
diclofenac 0.1% reported less pain than the control group on both pain scales 2,
4, 12, and 24 hours after surgery, with the maximum benefit at 4 hours (P=.02).
Fewer patients in the diclofenac group (76.0%) than in the control group (91.3%)
used oral pain and/or anxiolytic medications during the first 24 hours after
surgery (P=.25). Ninety-eight eyes had an uncorrected distance visual acuity of
20/40 or better. Mild peripheral diffuse lamellar keratitis accounted for the
majority of perioperative complications (n = 15).
CONCLUSION: Pain after femtosecond laser-assisted LASIK was mild and was reduced
with a single dose of topical diclofenac sodium 0.1% given immediately after
surgery.
|